Dow Jones
39.169,52 +50,66 (+0,13%) Nasdaq
17.879,30 +146,70 (+0,83%) Nikkei 225
39.631,06 +47,98 (+0,12%) EUR/USD
1,0740 -0,0002 (-0,02%) Bitcoin EUR
58.529,05 +184,09 (+0,32%) CMC Crypto 200
1.341,56 +39,49 (+3,03%)
Silo Pharma, Inc. (SILO)
Dopo ore:
| Chiusura precedente | 0,9705 |
| Aperto | 1,0000 |
| Denaro | 0,9522 x 100 |
| Domanda | 1,0400 x 100 |
| Min-Max giorno | 0,9600 - 1,0000 |
| Intervallo di 52 settimane | 0,9110 - 3,0500 |
| Volume | |
| Media Volume | 274.891 |
| Capitalizzazione | 3,628M |
| Beta (mensile su 5 anni) | 1,48 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,1700 |
| Prossima data utili | 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireSilo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
Human tissue study assessed SPU-21’s efficiency, optimization, and binding affinity ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive data from a preclinical study investigating the binding affinity and optimization of SPU-21 liposomal joint homing peptide in human synovial tissue surrounding joints
- GlobeNewswire
Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
Study to test effectiveness of Instructional System Designs (ISD) model for Intranasal SPC-15 ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a human factor study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD). The study will evalu
- GlobeNewswire
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that based on positive SPC-15 pre-clinical data, it is working with Kymanox as its regulatory partner to assist with the preparation of a pre-Investigational New
